mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Wilfredo F. Garcia-Beltran,K. S. St. Denis,Angelique Hoelzemer,Evan C. Lam,Adam Nitido,M. Sheehan,Cristhian Berríos,Onosereme Ofoman,Christina C. Chang,Blake M. Hauser,Jared Feldman,Alex Roederer,David Gregory,Mark C. Poznansky,Aaron G. Schmidt,A. John Iafrate,Vivek Naranbhai,Alejandro B. Balazs +17 more
TLDR
In this article , the authors measured the neutralization potency of sera from 88 mRNA-1273, 111 BNT162b, and 40 Ad26.1.1/B.COV2.About:
This article is published in Cell.The article was published on 2022-01-01 and is currently open access. It has received 787 citations till now. The article focuses on the topics: Medicine & Neutralization.read more
Citations
More filters
Journal ArticleDOI
Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current COVID‐19 vaccines
Yusha Araf,Fariya Akter,Yan-Dong Tang,Rabeya Fatemi,Sorwer Alam Parvez,Chunfu Zheng,Golzar Hossain +6 more
TL;DR: This review focused on the genomics, transmission, and effectiveness of vaccines against the Omicron variant, which will be helpful for further investigation of a new variant of SARS‐CoV‐2.
Journal ArticleDOI
SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron
Alison Tarke,Camila H. Coelho,Zeli Zhang,Jennifer M. Dan,Esther Dawen Yu,Nils Methot,Nathan Bloom,Benjamin Goodwin,Elizabeth J. Phillips,Simon Mallal,John Sidney,Gilberto Filaci,Daniela Weiskopf,Ricardo da Silva Antunes,Shane Crotty,Alba Grifoni,Alessandro Sette +16 more
TL;DR: In this paper , the authors address whether T cell responses induced by different vaccine platforms (mRNA-1273, BNT162b2, Ad26.COV2.S, and NVX-CoV2373) cross-recognize early SARS CoV-2 variants.
Journal ArticleDOI
T cell responses to SARS-CoV-2 spike cross-recognize Omicron
Roanne Keeton,Marius Belmondo Tincho,Amkele Ngomti,Richard Baguma,N. Benede,Akiko Suzuki,Khadija Khan,Sandile Cele,Mallory Bernstein,Farina Karim,Sharon Madzorera,Thandeka Moyo-Gwete,M. Mennen,S. Skelem,M. Adriaanse,Daniel Mutithu,Olukayode O. Aremu,Cari Stek,Elsa Du Bruyn,M. A. Van Der Mescht,Zelda de Beer,T. R. de Villiers,Anne Brunhilde Bodenstein,Gretha van den Berg,Adriano Mendes,Amy Strydom,Marietjie Venter,Jennifer Giandhari,Yeshnee Naidoo,Sureshnee Pillay,Houriiyah Tegally,Alba Grifoni,Daniela Weiskopf,Alessandro Sette,Robert J. Wilkinson,Tulio de Oliveira,Linda-Gail Bekker,Glenda Gray,Veronica Ueckermann,Theresa M. Rossouw,Michael T. Boswell,Jinal N. Bhiman,Penny L. Moore,Alex Sigal,Ntobeko A.B. Ntusi,Wendy A. Burgers,Catherine Riou +46 more
TL;DR: In this paper , the authors assessed the ability of T cells to react to Omicron spike protein in participants who were vaccinated with Ad26.S or BNT162b2, or unvaccinated convalescent COVID-19 patients.
Journal ArticleDOI
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
Hung Fu Tseng,Bradley Ackerson,Yi Luo,Lina S. Sy,Carla A. Talarico,Yun Tian,Katia Bruxvoort,Julia Tubert,Ana Florea,J.-H. Ku,Soon Kyu Choi,Harpreet S. Takhar,M. Aragones,Lei Qian +13 more
TL;DR: In this paper , a test-negative case-control study was conducted to evaluate mRNA-1273 vaccine effectiveness against infection and hospitalization with Omicron (B.1.529) variant.
Journal ArticleDOI
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
Eddy Perez-Then,Carolina Lucas,V. Monteiro,Marija Miric,Vivian Brache,Leila Cochon,Chantal B.F. Vogels,Amyn A. Malik,Elena De la Cruz,Aidelis Jorge,Margarita De Los Santos,Patricia Leon,Mallery I. Breban,K. Billig,Inci Yildirim,Claire Pearson,Randy Downing,Emily Gagnon,Anthony Muyombwe,Jafar Razeq,Melissa Campbell,Albert I. Ko,Saad B. Omer,Nathan D. Grubaugh,Sten H. Vermund,Akiko Iwasaki +25 more
TL;DR: In this paper , the authors evaluated the effects of a heterologous BNT162b2 mRNA vaccine booster on the humoral immunity of participants who had received a two-dose regimen of CoronaVac, an inactivated vaccine used globally.
References
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
David S. Khoury,Deborah Cromer,Arnold Reynaldi,Timothy E. Schlub,Timothy E. Schlub,Adam K. Wheatley,Jennifer A Juno,Kanta Subbarao,Stephen J. Kent,Stephen J. Kent,Stephen J. Kent,James A. Triccas,Miles P. Davenport +12 more
TL;DR: It is shown that neutralization level is highly predictive of immune protection, and an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic is provided.
Journal ArticleDOI
A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology.
Andrew Rambaut,Edward C. Holmes,Áine O'Toole,Verity Hill,John T. McCrone,Christopher Ruis,Louis du Plessis,Oliver G. Pybus +7 more
TL;DR: A rational and dynamic virus nomenclature that uses a phylogenetic framework to identify those lineages that contribute most to active spread and is designed to provide a real-time bird’s-eye view of the diversity of the hundreds of thousands of genome sequences collected worldwide.
Journal ArticleDOI
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
Jamie Lopez Bernal,Nick Andrews,Charlotte Gower,Eileen Gallagher,Ruth Simmons,Simon Thelwall,Julia Stowe,Elise Tessier,Natalie Groves,Gavin Dabrera,Richard H. Myers,Colin Campbell,Gayatri Amirthalingam,Matt Edmunds,Maria Zambon,Kevin E. Brown,Susan Hopkins,Meera Chand,Mary Ramsay +18 more
TL;DR: The B.617.1.2 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Coronavirus disease 2019 (Covid-19), has contributed to the development of the disease.
Journal ArticleDOI
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
Jerald C. Sadoff,Glenda Gray,An Vandebosch,Vicky Cardenas,Georgi Shukarev,Beatriz Grinsztejn,Paul A. Goepfert,Carla Truyers,Hein Fennema,Bart Spiessens,Kim Offergeld,Gert Scheper,Kimberly L Taylor,Merlin L. Robb,John J. Treanor,Dan H. Barouch,Jeffrey J. Stoddard,Martin Ryser,Mary A. Marovich,Kathleen M. Neuzil,Lawrence Corey,Nancy Cauwenberghs,Tamzin Tanner,Karin Hardt,Javier Ruiz-Guiñazú,Mathieu Le Gars,Hanneke Schuitemaker,Johan Van Hoof,Frank Struyf,Macaya Douoguih +29 more
TL;DR: A single dose of Ad26.COV2.S protected against symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection and was effective against severe–critical disease, including hospitalization and death, in an international, randomized, double-blind, placebo-controlled, phase 3 trial.